natgillin/translations-raw huggingface dataset:
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin together experienced the development of heart failure. 
Nekateri bolniki z dalj časa trajajočo sladkorno boleznijo tipa 2 in boleznijo srca ali prebolelo možgansko kapjo, ki so bili zdravljeni z pioglitazonom in insulinom skupaj, so izkusili razvoj srčnega popuščanja.
Frequency of adverse reactions Pioglitazone Glimepiride Tandemact 
Pogostnost neželenih učinkov Pioglitazon Glimepirid Tandemact
This may affect your ability to drive or use machines. 
To lahko vpliva na sposobnost upravljanja vozil in strojev.
Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible. 
Tudi če imate zamegljen vid in se ta simptom poslabša, se čim prej posvetujte s svojim zdravnikom.
Hepatobiliary disorders6 hepatitis very rare very rare impairment of liver function (with cholestasis and jaundice) 
Bolezni jeter, žolčnika in žolčevodov6 Hepatitis zelo redki zelo redki okvara delovanja jeter (s holestazo in zlatenico)
You may also experience a reduction in blood count (anaemia). 
Lahko se pojavi tudi slabokrvnost (anemija).
3 Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. 
3 V poročilih po pridobitvi dovoljenja za promet so poročali o preobčutljivostnih reakcijah pri bolnikih zdravljenih s pioglitazonom.
Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). 
Neželeni učinki, o katerih so poročali v dvojno slepih študijah in izkušnjah iz obdobja trženja zdravila so našteti spodaj in sicer po razredih organskih sistemov in absolutni pogostnosti, kot je priporočeno po MedDRA. Pogostnosti so določene kot: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz obstoječih podatkov).
- The other ingredients are cellulose microcrystalline, croscarmellose sodium, hydroxypropylcellulose, lactose monohydrate (see section 2 ‘Tandemact contains lactose monohydrate'), magnesium stearate and polysorbate 80. 
- Druge sestavine zdravila so mikrokristalna celuloza, premreženi natrijev karmelozat, hidroksipropilceluloza, laktoza monohidrat (glejte poglavje 2 “Zdravilo Tandemact vsebuje laktozo monohidrat”), magnezijev stearat in polisorbat 80.
Pioglitazone did not cause statistically significant increases in LDL-cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide. 
Pioglitazon ni povzročil statistično pomembnih povišanj ravni LDL holesterola v primerjavi s placebom, pri metforminu in gliklazidu pa so opazili znižanja teh vrednosti.
Glimepiride binds with a high exchange rate to a beta cell membrane protein which is associated with the ATP-sensitive potassium channel but which is different from the usual sulphonylurea binding site. 
Glimepirid se z veliko hitrostjo izmenjave veže na membransko beljakovino celic beta, povezano s kalijevimi kanalčki, občutljivimi za ATP, vendar se mesto njegove vezave razlikuje od običajnega mesta vezave sulfonilsečnin.
Liver enzymes should be checked prior to the initiation of therapy with Tandemact in all patients. 
Jetrne encime je treba pri vseh bolnikih kontrolirati pred uvedbo zdravljenja z zdravilom Tandemact.
Pioglitazone or placebo was added to existing antidiabetic and cardiovascular therapy for up to 3.5 years. 
Obstoječi antidiabetični in kardiovaskularni terapiji so 3,5 leta dodajali pioglitazon ali placebo.
In PROactive, a cardiovascular outcome study, 5,238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. 
V PROaktivni študiji kardiovaskularnega izida je bilo 5238 bolnikov s sladkorno boleznijo tipa 2 in že prej obstoječimi težjimi makrovaskularnimi boleznimi naključno dodatno do 3,5 let zdravljenih s pioglitazonom ali placebom k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju.
No unchanged substance was detected in the urine. 
V urinu se nespremenjena učinkovina ni pojavila.
Elderly Steady state pharmacokinetics are similar in patients age 65 and over and young subjects. 
Farmakokinetiki stanja dinamičnega ravnovesja sta pri bolnikih, starih 65 let in več, ter mladih osebah podobni.
The following data are findings in studies performed with pioglitazone or glimepiride individually. 
Naslednji podatki so bili ugotovljeni pri posamičnih raziskavah pioglitazona ali glimepirida.
Rare changes in haematology have been observed with glimepiride treatment (see section 4.8). 
Pri zdravljenju z glimepiridom so bile opažene redke spremembe v hematologiji (glejte poglavje 4.8).
Inform your doctor as soon as possible if you develop symptoms suggesting a problem with your liver (like feeling sick without explanations, vomiting, stomach ache, tiredness, loss of appetite and/or dark urine) as your liver function should be checked. 
Obvestite svojega zdravnika kakor hitro je mogoče, če se pojavijo simptomi, ki kažejo na težave z jetri (npr. nepojasnjeno siljenje na bruhanje, bruhanje, bolečine v trebuhu, utrujenost, izguba apetita in/ali temen urin), ker je treba preveriti delovanje jeter.
Moderate to severe thrombocytopenia, leucopenia, erythrocytopenia, granulocytopenia, agranulocytosis, haemolytic anaemia and pancytopenia may occur rarely (≥ 1/10,000 to < 1/1,000) (see section 4.4). 
Zmerna do huda trombocitopenija, levkopenija, eritrocitopenija, granulocitopenija, agranulocitoza, hemolitična anemija in pancitopenija se lahko pojavijo redko (≥ 1/10.000 do < 1/1.000) (glejte poglavje 4.4).
Glimepiride increases very rapidly the number of active glucose transport molecules in the plasma membranes of muscle and fat cells, resulting in stimulated glucose uptake. 
Glimepirid zelo hitro poveča število molekul za aktivni transport glukoze v plazemskih membranah mišičnih in maščobnih celic; posledica je stimuliran privzem glukoze.
Eye disorders visual disturbance4 
Očesne bolezni motnje vida4
In combination trials pioglitazone added to a sulphonylurea resulted in a mean weight increase over one year of 2.8 kg. 
V preskušanjih kombiniranega zdravljenja je pioglitazon, dodan sulfonilsečnini, povzročil povprečno povečanje telesne mase v enem letu za 2,8 kg.
Do not use this medicine after the expiry date which is stated on the carton and the blister after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na pretisnem omotu poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Glimepiride increases the activity of the glycosyl-phosphatidylinositol-specific phospholipase C which may be correlated with the induced lipogenesis and glycogenesis in isolated fat and muscle cells. 
Glimepirid poveča aktivnost za glikozil-fosfatidilinozitol specifične fosfolipaze C, kar je morda povezano z indukcijo lipogeneze in glikogeneze, ki jo zdravilo povzroči v izoliranih maščobnih in mišičnih celicah.
9 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 - 3 kg over one year. 
9 V kontroliranih preskušanjih s primerjalno učinkovino je bilo povprečno povečanje telesne mase pri pioglitazonu, dajanemu kot monoterapija, 2-3 kg v enem letu.
In clinical trials with pioglitazone and sulphonylurea monotherapy or in combination there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention. 
V kliničnih preskušanjih z monoterapijo ali kombinacijo pioglitazona in sulfonilsečnine so opažali pridobivanje telesne mase, odvisno od odmerka, ki je morda posledica nabiranja maščob, v nekaterih primerih pa je povezano z zastajanjem tekočine.
In patients with renal impairment, plasma concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. 
Pri bolnikih z okvaro ledvic so plazemske koncentracije pioglitazona in njegovih presnovkov nižje kot pri osebah z normalnim delovanjem ledvic, vendar je peroralni očistek izvorne učinkovine podoben.
If patients are receiving pioglitazone in combination with a sulphonylurea other than glimepiride, patients should be stabilised with concomitant pioglitazone and glimepiride before switching to Tandemact. 
Bolnike, ki prejemajo pioglitazon v kombinaciji z drugimi sulfonilsečninami (razen glimepirida), je treba pred prehodom na zdravilo Tandemact stabilizirati s hkratnim dajanjem pioglitazona in glimepirida.
Treatment of overdose of Tandemact primarily consists of preventing absorption of glimepiride by inducing vomiting and then drinking water or lemonade with activated charcoal (adsorbent) and sodium-sulphate (laxative). 
V primeru prevelikega odmerka zdravila Tandemact je potrebno preprečiti absorpcijo glimepirida s spodbujanjem bruhanja, čemur naj sledi pitje vode ali limonade z aktivnim ogljem (adsorbent) in natrijevim sulfatom (odvajalo).
If a patient wishes to become pregnant, treatment with Tandemact should be discontinued. 
Če bolnica želi zanositi, je treba zdravljenje z zdravilom Tandemact prekiniti.
Alcohol intake may potentiate or weaken the hypoglycaemic action of glimepiride in an unpredictable fashion. 
Pitje alkohola lahko nepredvidljivo poveča ali zmanjša hipoglikemično delovanje glimepirida.
It is recommended, therefore, that patients treated with Tandemact undergo periodic monitoring of liver enzymes. 
Zato je priporočeno, da pri bolnikih, zdravljenih z zdravilom Tandemact, redno spremljate vrednosti jetrnih encimov.
Preclinical effects observed occurred at exposures sufficiently in excess of the maximum human exposure as to indicate little relevance to clinical use, or were due to the pharmacodynamic action (hypoglycaemia) of the compound. 
Predklinično so učinke glimepirida opazili samo pri izpostavljenosti, ki je močno presegala največjo izpostavljenost pri človeku, kar kaže na majhen pomen za klinično uporabo, ali jih je povzročil njegov farmakodinamični učinek (hipoglikemija).
The observed excess risk of fractures for women on pioglitazone in this study is therefore 0.5 fractures per 100 patient years of use. 
Opazovano povečano tveganje za zlom pri ženskah v skupini s pioglitazonom v tej študiji je torej 0,5 zlomov na 100 bolnikov-let uporabe.
The following medicines can increase or decrease the blood sugar lowering effect of Tandemact: - H2 antagonists (to treat stomach ulcers) - beta-blockers, clonidine, guanethidine and reserpine (to treat high blood pressure or heart failure). 
Naslednja zdravila lahko povečajo ali zmanjšajo učinek zdravila Tandemact na zniževanje ravni sladkorja v krvi: - H2 antagonisti (za zdravljenje želodčnih razjed) - beta blokatorji, klonidin, gvanetidin in rezerpin (za zdravljenje visokega krvnega tlaka ali srčnega popuščanja).
No animal studies have been conducted with the combined products of Tandemact. 
Raziskave s kombinacijo učinkovin v zdravilu Tandemact na živalih niso bile narejene.
How to take Tandemact 
Kako jemati zdravilo Tandemact
If you experience this symptom for the first time, talk to your doctor as soon as possible. 
Če izkusite ta simptom prvič, se čim prej posvetujte s svojim zdravnikom.
Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure (see section 4.4). 
O srčnem popuščanju so poročali tudi v obdobju trženja pioglitazona, in sicer pogosteje pri uporabi pioglitazona v kombinaciji z insulinom ali pri bolnikih z anamnezo srčnega popuščanja (glejte poglavje 4.4).
Studies in human volunteers have shown Tandemact to be bioequivalent to the administration of pioglitazone and glimepiride given as separate tablets. 
Raziskave pri zdravih prostovoljcih so pokazale, da je zdravilo Tandemact bioekvivalentno sočasnemu jemanju pioglitazona in glimepirida kot dveh posameznih tablet.
Tandemact combines two antihyperglycaemic active substances with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: pioglitazone, a member of the thiazolidinedione class and glimepiride, a member of the sulphonylurea class. 
Zdravilo Tandemact je kombinacija dveh antihiperglikemičnih učinkovin s komplementarnim mehanizmom delovanja, namenjeno pa je izboljšanju urejenosti glikemije pri bolnikih s sladkorno boleznijo tipa 2: pioglitazona iz skupine tiazolidindionov in glimepirida iz skupine sulfonilsečnin.
Your doctor will advise you to discontinue this medicine. 
Zdravnik vam bo svetoval, da zdravila Tandemact ne jemljete.
coumarin derivatives such as warfarin (to treat heart or blood problems) - allopurinol, probenecid, sulfinpyrazone (to treat gout) - cyclophosphamide, ifosfamide, trofosfamide (to treat cancer) - fenfluramine (to reduce weight) - tritoqualine (to treat allergies) 
derivati kumarina, kot je varfarin (za zdravljenje bolezni srca ali krvi) - alopurinol, probenecid, sulfinpirazon (za zdravljenje protina) - ciklofosfamid, ifosfamid, trofosfamid (za zdravljenje raka) - fenfluramin (za zmanjšanje telesne mase) - tritokvalin (za zdravljenje alergij)
Tandemact is contra-indicated during breast-feeding (see section 4.3). 
Zdravilo Tandemact je kontraindicirano med dojenjem (glejte poglavje 4.3).
Skin and subcutaneous tissue disorders sweating uncommon hypersensitivity to light very rare very rare urticaria2 
Bolezni kože in podkožja Znojenje občasni preobčutljivost na svetlobo zelo redki zelo redki koprivnica2
rare rare 
redki redki
1 Moderate to severe thrombocytopenia, leucopenia, erythrocytopenia, granulocytopenia, agranulocytosis, haemolytic anaemia and pancyto-penia may occur. 
1 Lahko se pojavi zmerna do huda trombocitopenija, levkopenija, eritrocitopenija, agranulocitopenija, agranulocitoza, hemolitična anemija in pancitopenija.
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or other sulphonylureas or sulphonamides - Cardiac failure or history of cardiac failure (NYHA stages I to IV) - Current bladder cancer or a history of bladder cancer - Uninvestigated macroscopic haematuria - Hepatic impairment - Type 1 diabetes mellitus - Diabetic coma - Diabetic ketoacidosis - Severe renal function disorders (creatinine clearance < 30 ml/min) - Pregnancy - Breast-feeding (see section 4.6) 
- preobčutljivosti na učinkovine ali katero koli pomožno snov, navedeno v poglavju 6.1 ali druge sulfonilsečnine ali sulfonamide - srčnemu popuščanju ali anamnezi srčnega popuščanja (klasifikacija NYHA, stadiji I do IV) - raku mehurja ali raku mehurja v anamnezi - neraziskani makroskopski hematuriji - okvari jeter - sladkorni bolezni tipa 1 - diabetični komi - diabetični ketoacidozi - hudih motnjah ledvičnega delovanja (očistek kreatinina < 30 ml/min) - nosečnosti - dojenju (glejte poglavje 4.6)
Your doctor will ask you to have blood tests periodically during treatment with Tandemact. 
Zdravnik vam bo v času zdravljenja z zdravilom Tandemact naročil, da opravljate redne krvne preglede.
Women of childbearing potential / Contraception in males and females Tandemact is not recommended in women of childbearing potential not using contraception. 
Zdravilo Tandemact se ne priporoča pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
When meals are taken at irregular hours or skipped altogether, treatment with Tandemact may lead to hypoglycaemia due to the sulphonylurea component. 
Pri nerednih ali izpuščenih obrokih lahko zdravljenje z zdravilom Tandemact zaradi sulfonilsečnine povzroči hipoglikemijo.
not known not known rash2 
neznana neznana srbenje2
What Tandemact contains - The active substances are pioglitazone and glimepiride. 
Kaj vsebuje zdravilo Tandemact - Učinkovini sta pioglitazon in glimepirid.
Since glimepiride belongs to the chemical class of sulfonylurea medicinal products, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered. 
Ker sodi glimepirid kemijsko v skupino zdravil, ki so derivati sulfonilsečnine, je potrebna pri bolnikih s pomanjkanjem G6PD previdnost.
Talk to your doctor or pharmacist before taking Tandemact (see also section 4) - if you have a problem with your heart. 
Pred začetkom jemanja zdravila Tandemact se posvetujte z zdravnikom ali s farmacevtom (glejte tudi poglavje 4):
In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. 
10 V kliničnih preskušanjih pioglitazona je bila incidenca povišanih vrednosti ALT, višjih kot trikratna zgornja meja normalnih vrednosti, enaka kot pri placebu, vendar nižja kot v primerjalnih skupinah metformina ali sulfonilsečnine.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions reports of bone fracture from randomised, controlled, double blind clinical trials (see section 4.8). 
V skupni analizi neželenih učinkov zlomov kosti iz randomiziranih, kontroliranih, dvojno slepih kliničnih preskušanj (glejte poglavje 4.8).
If large quantities have been ingested, gastric lavage is indicated, followed by activated charcoal and sodium-sulphate. 
V primeru zaužitja velikih količin, je indicirano izpiranje želodca, ki mu sledi zaužitje aktivnega oglja in natrijevega sulfata.
Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells. 
Glimepirid deluje predvsem s spodbujanjem izločanja insulina iz celic beta v pankreasu.
Hypoglycaemia (low blood sugar) has been reported uncommonly (may affect up to 1 in 100 people) in patients taking Tandemact. 
O hipoglikemiji (nizka raven sladkorja v krvi) so poročali občasno (pri največ 1 od 100 bolnikov) pri bolnikih, ki jemljejo zdravilo Tandemact.
- headache - inflammation of the sinuses (sinusitis) - vertigo - abnormal vision - sweating - tiredness - difficulty sleeping (insomnia) - decreased blood sugar - sugar in urine - proteins in urine - increased appetite - increase of an enzyme called lactic dehydrogenase (LDH) 
- znižan krvni sladkor - sladkor v urinu - beljakovine v urinu - povečan apetit - povišanje encima, ki se imenuje laktatna dehidrogenaza (LDH)
Sulphonylureas regulate insulin secretion by closing the ATP-sensitive potassium channel in the beta cell membrane. 
Sulfonilsečnine uravnavajo izločanje insulina z zaprtjem za ATP odvisnih kalijevih kanalčkov v membrani celic beta.
phenylbutazone, azapropazone and oxyfenbutazone insulin and oral antidiabetic products metformin salicylates and p-amino-salicylic acid anabolic steroids and male sex hormones chloramphenicol clarithromycin coumarin anticoagulants disopyramide fenfluramine fibrates angiotensin-converting enzyme (ACE) inhibitors fluoxetine allopurinol sympatholytics cyclo-, tro- and iphosphamides sulphinpyrazone certain long-acting sulphonamides tetracyclines 
fenilbutazon, azapropazon in oksifenbutazon insulin in peroralni antidiabetiki metformin salicilati in p-aminosalicilna kislina anabolni steroidi in moški spolni hormoni kloramfenikol klaritromicin kumarinski antikoagulansi dizopiramid fenfluramin fibrati zaviralci angiotenzinske konvertaze (zaviralci ACE) fluoksetin alopurinol simpatikolitiki ciklo-, tro- in ifosfamidi sulfinpirazon nekateri dolgo delujoči sulfonamidi tetracikilini zaviralci MAO kinolonski antibiotiki probenecid mikonazol pentoksifilin (velik parenteralen odmerek) tritokalin flukonazol
oestrogens and progestagens, saluretics, thiazide diuretics, thyroid stimulating agents, glucocorticoids, phenothiazine derivatives, chlorpromazine, adrenaline and sympathicomimetics, nicotinic acid (high doses) and nicotinic acid derivatives, laxatives (long-term use), phenytoin, diazoxide, glucagon, barbiturates and rifampicin. 
estrogeni in progestageni, saluretiki, tiazidni diuretiki, sredstva, ki stimulirajo ščitnico, glukokortikoidi, fenotiazinski derivati, klorpromazin, adrenalin in simpatikomimetiki, nikotinska kislina (veliki odmerki) in derivati nikotinske kisline, odvajala (dolgotrajna uporaba), fenitoin, diazoksid, glukagon, barbiturati in rifampicin acetozolamid
Therapy with Tandemact should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 x upper limit of normal) or with any other evidence of liver disease. 
Pri bolnikih s povišanimi izhodiščnimi vrednostmi jetrnih encimov (ALT > 2,5-kratna zgornja meja normalnih vrednosti) ali s kakršnimi koli drugimi znaki jetrne bolezni, zdravljenja z zdravilom Tandemact ne smemo začeti.
Blurred vision due to swelling (or fluid) at the back of the eye (macular oedema) has also been reported in patients taking Tandemact (frequency cannot be estimated from the available data). 
Pri bolnikih, ki jemljejo zdravilo Tandemact so poročali tudi o zamegljenem vidu zaradi otekline (ali tekočine) v zadnjem delu očesa (makularni edem) (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Treatment with Tandemact requires regular monitoring of glycaemic control. 
Pri zdravljenju z zdravilom Tandemact je potrebno redno spremljati glikemični nadzor.
The bioavailability of glimepiride after oral administration is complete. 
Biološka uporabnost glimepirida je po peroralnem dajanju popolna.
There have been rare reports of elevated liver enzymes and hepatocellular dysfunction during post-marketing experience with pioglitazone and glimepiride (see section 4.8). 
Iz izkušenj v obdobju trženja pioglitazona in glimepirida so poročali o redkih primerih povišanja jetrnih encimov in hepatocelularne disfunkcije (glejte poglavje 4.8).
Thiazolidinediones act primarily by reducing insulin resistance and sulphonylureas primarily by inducing insulin release from pancreatic beta cells. 
Tiazolidindioni primarno zmanjšujejo insulinsko rezistenco, primarni učinek sulfonilsečnin pa je spodbujanje sproščanja insulina iz beta celic v pankreasu.
The physiological response to acute physical exercise, reduction of insulin secretion, is still present under glimepiride. 
Zmanjšanje izločanja insulina, ki je fiziološki odziv na akutno telesno obremenitev, se med zdravljenjem z glimepiridom ohrani.
This is because some medicines can weaken or strengthen the effect of Tandemact on the level of sugar in your blood. 
Nekatera zdravila lahko zmanjšajo ali povečajo učinek zdravila Tandemact na raven sladkorja v krvi.
Tandemact contains lactose monohydrate 
Tablete vsebujejo laktozo monohidrat.
- anabolic steroids (supporting muscle build up) or male sex hormone replacement therapy - fluoxetine, MAO-inhibitors (to treat depression) - angiotensin-converting enzyme (ACE) inhibitors, sympatholytics, disopyramide, pentoxifylline, 
klaritromicin (za zdravljenje bakterijskih ali glivičnih okužb) - anabolični steroidi (podpirajo izgradnjo mišic) ali nadomestna terapija z moškimi spolnimi hormoni - fluoksetin, zaviralci MAO (za zdravljenje depresije) - zaviralci angiotenzinske konvertaze (zaviralci ACE), simpatolitiki, dizopiramid, pentoksifilin,
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Tandemact. 
Rak sečnega mehurja se lahko pojavi občasno (pri največ 1 od 100 bolnikov) pri bolnikih, ki jemljejo zdravilo Tandemact.
Glimepiride is transferred to the placenta. 
Glimepirid prehaja skozi placento.
There is no clinical trial experience of other oral anti-hyperglycaemic medicinal products added to treatment with Tandemact or concomitantly administered glimepiride and pioglitazone. 
Kliničnih izkušenj z zdravilom Tandemact v kombinaciji z drugimi peroralnimi antihiperglikemičnimi zdravili ali s sočasnim jemanjem glimepirida in pioglitazona ni.
Blood glucose should be closely monitored. 
Treba je skrbno nadzirati raven glukoze v krvi.
QUALITATIVE AND QUANTITATIVE COMPOSITION Tandemact 30 mg/2 mg tablets 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Tandemact 30 mg/2 mg tablete